Article Text

Download PDFPDF

Original article
Anti-TNF therapy in IBD exerts its therapeutic effect through macrophage IL-10 signalling
  1. Pim J Koelink1,
  2. Felicia M Bloemendaal1,2,
  3. Bofeng Li3,
  4. Liset Westera1,
  5. Esther W M Vogels1,
  6. Manon van Roest1,
  7. Anouk K Gloudemans4,
  8. Angelique B van 't Wout4,
  9. Hannelie Korf5,
  10. Séverine Vermeire5,
  11. Anje A te Velde1,
  12. Cyriel Y Ponsioen6,
  13. Geert RAM D'Haens6,
  14. J Sjef Verbeek7,
  15. Terrence L Geiger3,
  16. Manon E Wildenberg1,6,
  17. Gijs R van den Brink1,6
  1. 1Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam, The Netherlands
  2. 2Department of Gastroenterology and hepatology, Amsterdam UMC, Amsterdam, The Netherlands
  3. 3Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, USA
  4. 4Janssen Prevention Center of Janssen Vaccines & Prevention BV, Janssen Pharmaceutical Companies of Johnson & Johnson, Leiden, The Netherlands
  5. 5Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
  6. 6Gastroenterology & Hepatology, Amsterdam UMC, Amsterdam, The Netherlands
  7. 7Human Genetics, Leids Universitair Medisch Centrum, Leiden, The Netherlands
  1. Correspondence to Dr Pim J Koelink, Tytgat Insitute for Liver & Intestinal Research, Amsterdam UMC, Amsterdam 1105 BK, The Netherlands; p.j.koelink{at}amc.nl

Footnotes

  • PJK and FMB contributed equally.

  • Contributors PJK, FMB, LW, MEW, EWMV and MvR performed experiments and analysed and discussed the data. AKG, ABvtW, GRAMD’H and GRvdB discussed the data. TLG and BL provided the LysMcreIl10rafl/flRag1KO mice and discussed the data. JSV provided FcgRKO/Rag1KO mice and discussed the data. HK, SV, AAtV and CYP provided patient samples and discussed the data. GRvdB and PJK supervised the study. PJK, FMB and GRvdB wrote the manuscript with input of all the authors.

  • Funding This work was supported by a unrestricted research grant from the Janssen Prevention Center of Janssen Vaccines & Prevention BV, Leiden, the Netherlands, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and by Health Holland, Top Sector Life Sciences and Health.

  • Competing interests AKG and ABvtW are employees of Janssen Vaccines and Prevention B.V. GRvdB is currently an employee of Roche. CYP received research support from Takeda, speaker’s fees from Takeda, Abbvie and Dr. Falk Pharma, and consultancy fee from Takeda outside this work. Other authors declare no conflict of interest related to this work.

  • Patient consent for publication Not required.

  • Ethics approval The Medical Ethical Committee of the Amsterdam UMC(METC 2009_113) and the Institutional Review Board of the Hospital in Leuven (B322201213950/S53684) approved this study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

View Full Text

Statistics from Altmetric.com

Footnotes

  • PJK and FMB contributed equally.

  • Contributors PJK, FMB, LW, MEW, EWMV and MvR performed experiments and analysed and discussed the data. AKG, ABvtW, GRAMD’H and GRvdB discussed the data. TLG and BL provided the LysMcreIl10rafl/flRag1KO mice and discussed the data. JSV provided FcgRKO/Rag1KO mice and discussed the data. HK, SV, AAtV and CYP provided patient samples and discussed the data. GRvdB and PJK supervised the study. PJK, FMB and GRvdB wrote the manuscript with input of all the authors.

  • Funding This work was supported by a unrestricted research grant from the Janssen Prevention Center of Janssen Vaccines & Prevention BV, Leiden, the Netherlands, part of the Janssen Pharmaceutical Companies of Johnson & Johnson, and by Health Holland, Top Sector Life Sciences and Health.

  • Competing interests AKG and ABvtW are employees of Janssen Vaccines and Prevention B.V. GRvdB is currently an employee of Roche. CYP received research support from Takeda, speaker’s fees from Takeda, Abbvie and Dr. Falk Pharma, and consultancy fee from Takeda outside this work. Other authors declare no conflict of interest related to this work.

  • Patient consent for publication Not required.

  • Ethics approval The Medical Ethical Committee of the Amsterdam UMC(METC 2009_113) and the Institutional Review Board of the Hospital in Leuven (B322201213950/S53684) approved this study.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.